22 October 2018 in Cancer Cell International
Primary or acquired resistance to cetuximab often occurs during targeted therapy in metastatic colorectal cancer (mCRC) patients. In many cancers, the key role of the long noncoding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) in anticancer drug resistance has been confirmed. Emerging evidence has shown that specific exosomal lncRNAs may serve as meaningful biomarkers. In this study, we hypothesize that exosomal UCA1 might predict the response to cetuximab in CRC patients. First, acquired cetuximab-resistant cell lines were generated, and UCA1 expressions in these cells and their exosomes were compared. We also systematically evaluate the stability of exosomal UCA1. Thereafter, the predictive value of exosomal UCA1 in CRC patients treated with cetuximab was evaluated. Finally, through cell apoptosis assays and immunofluorescence staining, we analyzed the role of UCA1-containing exosomes in conferring cetuximab resistance. UCA1 expression was markedly higher in cetuximab-resistant cancer cells and their exosomes. Exosomal UCA1 was shown to be detectable and stable in serum from CRC patients. In addition, circulating UCA1-containing exosomes could predict the clinical outcome of cetuximab therapy in CRC patients, and UCA1 expression was considerably higher in the progressive disease/stable disease patients than in the partial response/complete response patients. Furthermore, exosomes derived from cetuximab-resistant cells could alter UCA1 expression and transmit cetuximab resistance to sensitive cells. We discovered a novel role of UCA1-containing exosomes, showed their capability to transmit drug resistance and investigated their potential clinical use in predicting cetuximab resistance.
3 November 2025 in Cell Communication and Signaling
Among white blood cells (WBCs), neutrophils are the most abundant and multifunctional immune cells in the blood, which are also involved in diverse physiological and pathological processes, particularly affecting the deterioration of the tumor. Neutrophil extracellular traps (NETs), composed of chromatin DNA studded with granule proteins, play a crucial role in reactive sterile inflammation. Recently, neutrophils have garnered focus in cancer research due to their participation in cancer initiation, proliferation and metastasis. As important players in the tumor microenvironment (TME), tumor-associated neutrophils (TANs) are viewed as “a double-edged sword” in cancer pathophysiology.In this review, we introduce the NETs formation and associated signaling pathways. Meanwhile, recent studies on the mechanisms through by which neutrophils could promote tumors development will be described. Additionally, we outline the complex complicated molecular mechanisms underlying cancer therapy resistances and associated preface tumor treatment. Finally, we highlight latest advances in NETs-targeting treatment strategies designed to improve the efficacy of cancer therapies.